What is Disc Medicine's G&A?

Disc Medicine (IRON) reported G&A of $8.17M in Q3 2024.

How has Disc Medicine's G&A changed year-over-year?

Disc Medicine's G&A increased by 80.0% year-over-year, from $4.54M to $8.17M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Disc Medicine IRON G&A

Discontinued — last reported Q3 '24

G&A at other companies

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Beam TherapeuticsBEAM

$34.43M+23.2%

Segments

By segment

See full

Significant Segment Expense Category-$9.03M-31.7%

Other financials

Income statement

See full

Operating income-$69.5M-74.0%

Net income-$63.5M-86.3%

EPS (diluted)-$1.65-61.8%

Balance sheet

See full

Cash & equivalents$88.9M-27.5%

Total debt$31.1M+1.4%

Total equity$688.4M+4.3%

Total assets$750.2M+5.8%

Cash flow

See full

Operating cash flow-$62.2M-50.4%

CapEx--100%

Free cash flow-$62.2M-47.4%

Valuation

See full

Market cap$2.69B+42.2%

Enterprise value$2.63B+46.7%

Returns & leverage

See full

Return on equity-35.8%+41.3pp

Debt / equity0×0.0×

Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Disc Medicine’s 10-Q, filed November 12, 2024, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Disc Medicine's G&A?: Disc Medicine (IRON) reported G&A of $8.17M in Q3 2024.
How has Disc Medicine's G&A changed year-over-year?: Disc Medicine's G&A increased by 80.0% year-over-year, from $4.54M to $8.17M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.